NCT06763328View on ClinicalTrials.gov

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

June 16, 2029

Study Completion Date

June 16, 2029

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Invasive Breast Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Educational Intervention

Receive standard of care healthy diet and exercise handouts

DRUG

Extended Release Metformin Hydrochloride

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

91010

RECRUITING

City of Hope Medical Center, Duarte

92093

NOT_YET_RECRUITING

UC San Diego Moores Cancer Center, La Jolla

92521

NOT_YET_RECRUITING

University of California-Riverside, Riverside

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER